Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Di Mauro, Concetta ^a   Pesapane, Ada ^a   Formisano, Luigi ^a   Rosa, Roberta ^a   D'Amato, Valentina ^a   Ciciola, Paola ^a   Servetto, Alberto ^a   Marciano, Roberta ^a   Orsini, Roberta Clara ^a   Monteleone, Francesca ^a,b   Zambrano, Nicola ^a,b   Fontanini, Gabriella ^c   Servadio, Adele ^c   Pignataro, Giuseppe ^d   Grumetto, Lucia ^a   Lavecchia, Antonio ^a   Bruzzese, Dario ^a   Iaccarino, Antonino ^a   Troncone, Giancarlo ^a   Veneziani, Bianca Maria ^a   Montuori, Nunzia ^a   De Placido, Sabino ^a   Bianco, Roberto ^a   more..

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RAS PROTEIN; UROKINASE RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL ADHESION; CELL MOTION; COLORECTAL TUMOR; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; MOUSE; MUTATION; NEOPLASM; NON SMALL CELL LUNG CANCER; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL MOVEMENT; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; RAS PROTEINS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85028026897     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-10062-1     Document Type: Article

References (37)

1. Montuori, N. et al. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost. 109, 309-318 (2013).
2. Mazar, A. P. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: Implications for tumor progression and therapy. Clin Cancer Res. 14, 5649-5655 (2008).
3. Montuori, N. et al. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma. Int J Cancer. 105, 353-360 (2003).
4. Almasi, C. E. et al. Urokinase receptor forms in serum from non-small cell lung cancer patients: Relation to prognosis. Lung Cancer. 74, 510-515 (2011).
5. Lomholt, A. F., Høyer-Hansen, G., Nielsen, H. J. & Christensen, I. J. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. Br J Cancer. 101, 992-997 (2009).
6. Lomholt, A. F., Christensen, I. J., Høyer-Hansen, G. & Nielsen, H. J. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol. 49, 805-811 (2010).
7. Montuori, N., Visconte, V., Rossi, G. & Ragno, P. Soluble and cleaved forms of the urokinase-receptor: Degradation products or active molecules? Thromb Haemost. 93, 192-198 (2005).
8. Wei, Y. et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 269, 32380-32388 (1994).
9. Madsen, C. D., Ferraris, G. M., Andolfo, A., Cunningham, O. & Sidenius, N. uPAR-induced cell adhesion and migration: Vitronectin provides the key. J Cell Biol. 177, 927-939 (2007).
10. Lester, R. D., Jo, M., Montel, V., Takimoto, S. & Gonias, S. L. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 178, 425-436 (2007).
11. Van der Pluijm, G. et al. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am J Pathol. 159, 971-982 (2001).
12. Tang, C. H. & Wei, Y. The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci. 65, 1916-1932 (2008).
13. Montuori, N. & Ragno, P. Multiple activities of a multifaceted receptor: Roles of cleaved and soluble uPAR. Front Biosci (Landmark Ed). 14, 2494-2503 (2009).
14. Smith, H. W. & Marshall, C. J. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 11(1), 23-36 (2010).
15. De Paulis, A. et al. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J Immunol. 173, 5739-5748 (2004).
16. Liu, D., Aguirre Ghiso, J., Estrada, Y. & Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell. 1, 445-457 (2002).
17. Zannetti, A. et al. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res. 60, 1546-1551 (2000).
18. Luo, M. & Fu, L. W. Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res. 4, 608-628 (2014).
19. Rosa, R., Monteleone, F., Zambrano, N. & Bianco, R. In vitro and in vivo models for analysis of resistance to anticancer molecular therapies. Curr Med Chem. 21, 1595-1606 (2014).
20. Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).
21. Monteleone, F. et al. Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody. Proteomics. 13, 866-877 (2013).
22. Rea, V. et al. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion. Mol Cancer Ther. 12, 1402-1416 (2013).
23. Arun, Unni M., William, Lockwood W., Kreshnik, Zejnullahu, Shih-Queen, Lee-Lin, & Harold, Varmus. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. eLife. 4, e06907 (2015).
24. Formisano, L. et al. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. Oncotarget. 6(28), 26090-103 (2015).
25. Efimov, A. et al. Paxillin-dependent stimulation of microtubule catastrophes at focal adhesion sites. J Cell Sci. 121, 196-204 (2008).
26. Emami, J. In vitro - in vivo correlation: From theory to applications. J Pharm Pharm Sci. 9, 169-189 (2006).
27. Jurka, J. & Milosavljevic, A. Reconstruction and analysis of human Alu genes. J Mol Evol. 32, 105-121 (1991).
28. Troiani, T. et al. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open. 1, e000088 (2016).
29. Mazzieri, R., D'Alessio, S., Kenmoe, R. K., Ossowski, L. & Blasi, F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol Biol Cell. 17, 367-378 (2006).
30. Jo, M., Takimoto, S., Montel, V. & Gonias, S. L. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am J Pathol. 175, 190-200 (2009).
31. Madsen, C. D. & Sidenius, N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol. 87, 617-629 (2008).
32. Nalla, A. K. et al. Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma. PLoS One. 5, e13006 (2010).
33. Mani, T. et al. Small-molecule inhibition of the uPARuPA interaction: Synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem. 21, 2145-2155 (2013).
34. Liu, D., Zhou, D., Wang, B., Knabe, W. E. & Meroueh, S. O. A new class of orthosteric uPARuPA small-molecule antagonists are allosteric inhibitors of the uPARvitronectin interaction. ACS Chem Biol. 10, 1521-1534 (2015).
35. Heinemann, V. et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 108, 766-770 (2013).
36. Rosa, R. et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 19, 138-147 (2013).
37. Schneider, T., Osl, F., Friess, T., Stockinger, H. & Scheuer, W. V. Quantification of human Alu sequences by real-time PCR-an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis. 19, 571-582 (2002).